Cardiac AgeingNCT05775484
Exercise to Slow Cardiovascular Ageing Progression
An observational study of Cardiac Ageing and Exercise, run by National Heart Centre Singapore at 1 site in Singapore.
Trial summary
In ageing, deleterious alterations in cardiovascular (CV) structure and function increase risks of ageing-related cardiovascular disease (CVD). Investigators found that these CV alterations were associated with circulating serum metabolites, suggesting a metabolic basis to CV ageing. Read more about this study
- Who is it for?
- Ages 21 to 100 yearsHealthy volunteers can take part
- Conditions the study is for
- Cardiac Ageing, Exercise, Cardiovascular
- How many people
- 450 participants
- Where
- 1 siteSingapore
- Study dates
- 1 May 2023to 31 Dec 2050
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 100 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Recruited through research studies and community studies.
Who may be able to join
- Age >=21 years old
- Outdoor ambulant
Who cannot join
- Wheelchair or bed-bound
- Dementia
- Residing in sheltered or nursing home
- Cancer
- Participation in ongoing clinical trials that involve interventional drugs or devices
- Aneurysms
Show all 11Show fewer
- Acute infections (in the last six months)
- Uncontrolled thyrotoxicosis
- Neuromuscular, musculoskeletal or rheumatoid disorders that are exacerbated by exercise
- Uncontrolled asthma or chronic lung disease
- Restrictive lung disease
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Singapore1 site, 1 recruiting
- Recruiting
National Heart Centre Singapore
Singapore, Singapore, 169609
Angela Koh, M.D., 67042228, angela.koh.s.m@singhealth.com.sg
Angela Koh, M.D
About this study
In ageing, deleterious alterations in cardiovascular (CV) structure and function increase risks of ageing-related cardiovascular disease (CVD). Investigators found that these CV alterations were associated with circulating serum metabolites, suggesting a metabolic basis to CV ageing. Investigators hypothesize that modification of these metabolites by intervention, such as exercise, may retard CV alterations and reduce CVD in ageing.
Read the detailed description
Participants from each stratum will be randomized to receive either an exercise program intervention or no exercise. At the start and end of study, participants will undergo cardiovascular imaging and metabolic profiling. Investigators will determine if exercise can reverse high-risk metabolic profiles and improve cardiovascular structure and function.
Without clear mechanisms to explain cardiovascular ageing nor interventions known to retard cardiovascular ageing, our approach will provide much needed translational evidence to incorporate targeted interventions aimed at reducing cardiovascular disease risk in older populations.
- Conditions
- Cardiac Ageing, Exercise, Cardiovascular
- Medical subject headings
- Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| A | 1. Cardiovascular measurements Non-invasive brachial blood pressure machine Echocardiography 2. Bio-specimen collection 3. Six-minute walk test 4. Musculoskeletal Analysis 5. Cardiopulmonary exercise test | |
| B | 1. Cardiovascular measurements Non-invasive brachial blood pressure machine Echocardiography 2. Bio-specimen collection 3. Six-minute walk test 4. Musculoskeletal Analysis | |
| C | 1. Cardiovascular measurements Non-invasive brachial blood pressure machine Echocardiography 2. Bio-specimen collection 3. Six-minute walk test 4. Musculoskeletal Analysis | |
| D | 1. Cardiovascular measurements Non-invasive brachial blood pressure machine Echocardiography 2. Bio-specimen collection 3. Six-minute walk test (may require separate day visit to complete) 4. Musculoskeletal Analysis 5. Questionnaires |
What is being measured
The primary outcome is the main question the study is designed to answer.
Metabolite profiles
To measure changes in serum metabolite levels among participants pre and post exercise intervention.
Measured: 12 Months
Cardiovascular structure and function
To measure changes in CV structure and function (diastolic function, arterial stiffness) among participants.
Measured: 12 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Mar 2023
- Study start1 May 2023
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2050 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiac AgeingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 450 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Heart Centre Singapore
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05775484
- Sponsor's protocol ID
- 2022/2667
- Status last verified
- Apr 2025
- First submitted
- 10 Feb 2023
- Last updated
- 5 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exercise to Slow Cardiovascular Ageing Progression
- ClinicalTrials.gov ID
- NCT05775484
- Acronym / sponsor ID
- 2022/2667
- Conditions
- Cardiac Ageing, Exercise, Cardiovascular
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 450 participants (estimated)
- Lead sponsor
- National Heart Centre SingaporeUniversity, hospital or other
- Study start
- 1 May 2023 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2050 (estimated)
- First posted
- 20 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In ageing, deleterious alterations in cardiovascular (CV) structure and function increase risks of ageing-related cardiovascular disease (CVD). Investigators found that these CV alterations were associated with circulating serum metabolites, suggesting a metabolic basis to CV ageing. Investigators hypothesize that modification of these metabolites by intervention, such as exercise, may retard CV alterations and reduce CVD in ageing.
Detailed description
Participants from each stratum will be randomized to receive either an exercise program intervention or no exercise. At the start and end of study, participants will undergo cardiovascular imaging and metabolic profiling. Investigators will determine if exercise can reverse high-risk metabolic profiles and improve cardiovascular structure and function.
Without clear mechanisms to explain cardiovascular ageing nor interventions known to retard cardiovascular ageing, our approach will provide much needed translational evidence to incorporate targeted interventions aimed at reducing cardiovascular disease risk in older populations.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| A | – | –1. Cardiovascular measurements Non-invasive brachial blood pressure machine Echocardiography 2. Bio-specimen collection 3. Six-minute walk test 4. Musculoskeletal Analysis 5. Cardiopulmonary exercise test |
| B | – | –1. Cardiovascular measurements Non-invasive brachial blood pressure machine Echocardiography 2. Bio-specimen collection 3. Six-minute walk test 4. Musculoskeletal Analysis |
| C | – | –1. Cardiovascular measurements Non-invasive brachial blood pressure machine Echocardiography 2. Bio-specimen collection 3. Six-minute walk test 4. Musculoskeletal Analysis |
| D | – | –1. Cardiovascular measurements Non-invasive brachial blood pressure machine Echocardiography 2. Bio-specimen collection 3. Six-minute walk test (may require separate day visit to complete) 4. Musculoskeletal Analysis 5. Questionnaires |
Who may qualify
- Ages
- 21 to 100 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Recruited through research studies and community studies.
Key inclusion criteria (2 listed)
- Age >=21 years old
- Outdoor ambulant
Key exclusion criteria (11 listed)
- Wheelchair or bed-bound
- Dementia
- Residing in sheltered or nursing home
- Cancer
- Participation in ongoing clinical trials that involve interventional drugs or devices
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Metabolite profiles
Time frame: 12 Months
To measure changes in serum metabolite levels among participants pre and post exercise intervention.
Cardiovascular structure and function
Time frame: 12 Months
To measure changes in CV structure and function (diastolic function, arterial stiffness) among participants.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2025.
- Individual participant dataSharing planned: No
Related trials for Cardiac Ageing
Recruiting
Auricular Vagus Nerve Stimulation Mechanisms for HIV-Associated Peripheral Neuropathy
HIV Associated Polyneuropathy
Active, not recruitingPhase 2
Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]
Aging
Not yet recruitingObservational study
CHIP in Health and Disease
Clonal Hematopoiesis, Clonal Hematopoiesis of Indeterminate Potential
RecruitingObservational study
Multimodal Cardiovascular and Hepatic Population Imaging
Healthy Volunteers, Imaging Evaluation
Not yet recruiting
Community Physical Exercise Program in Chronic Disease
Osteoarthritis Pain, Myocardial Infarction (MI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiac Ageing and Exercise, run by National Heart Centre Singapore at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Metabolite profiles (time frame: 12 Months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2025.